NASDAQ$ABCL
AbCellera Biologics Inc. · Q4 2019 earnings
Q4 2019 earnings · · Investor relations
Briefing
AbCellera reported financial results for Q4 2021
AbCellera's Q4 2021 revenue reached $139.3 million, with royalties on bamlanivimab sales contributing $134.5 million and research fees accounting for $4.7 million. Net earnings for the quarter were $59.9 million, or $0.21 per share on a basic and $0.19 per share on a diluted basis.
- Q4 2021 revenue was $139.3 million, representing 37% of the total for 2021.
- Royalties on net sales of bamlanivimab generated $134.5 million in Q4 2021.
- Research fees contributed $4.7 million in Q4 2021.
- Net earnings for Q4 2021 were $59.9 million, or $0.21 per share on a basic and $0.19 per share on a diluted basis.
Headline financials
Revenue & EPS history
AbCellera · Revenue · Quarterly
$139M
Revenue by segment
AbCellera · $4.7M total across 1 segment · Q4 2019
- Research Fees$4.7M—100.0%
Forward guidance
AbCellera moves into 2022 with momentum and a strong cash position to continue to grow our business and to make investments that will increase the speed, efficiency, and scalability of our platform.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 19 quarterly earnings reports · overlaid with Q4 2019
-0.4%
Avg return
Earnings day
+0.7%
Avg return
5 days after
+0.2%
Avg return
30 days after
46%
11 / 24 earnings
Positive
+17.1%
Q2 2021
Best reaction
-13.9%
Q3 2025
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | +0.2% | -21.8% | -2.9% | |
| Q4 2025 | -1.5% | +18.6% | +1.6% | |
| Q3 2025 | -13.9% | -12.4% | -21.4% | |
| Q1 2025 | +1.0% | +2.0% | +21.4% | |
| Q4 2024 | -11.3% | -18.2% | -20.9% | |
| Q3 2024 | -0.4% | -1.1% | +6.2% | |
| Q2 2024 | -4.7% | -2.9% | -12.0% | |
| Q1 2024 | -6.6% | -6.8% | -8.0% | |
| Q4 2023 | -9.9% | -8.8% | -11.8% | |
| Q3 2023 | +14.1% | +6.8% | +17.2% | |
| Q2 2023 | -13.0% | -15.1% | -19.5% | |
| Q1 2023 | -9.1% | -14.1% | +3.0% | |
| Q4 2022 | -8.3% | -12.7% | -23.8% | |
| Q3 2022 | -1.7% | +13.1% | -7.2% | |
| Q2 2022 | +13.4% | +16.3% | -3.9% | |
| Q1 2022 | -12.0% | +11.2% | +29.1% | |
| Q4 2019 | +8.1% | +9.4% | +15.5% | |
| Q4 2021 | +8.1% | +9.4% | +15.5% | |
| Q3 2020 | -7.8% | -2.0% | -5.1% | |
| Q2 2018 | +16.3% | +10.3% | +25.0% | |
| Q2 2021 | +17.1% | +8.6% | +24.3% | |
| Q1 2018 | +0.1% | -5.2% | -24.1% | |
| Q1 2021 | +3.4% | +7.4% | -15.7% | |
| Q4 2018 | +7.8% | +24.1% | +21.3% | |
| Q3 2017 | — | — | — | |
| Q2 2017 | — | — | — | |
| Q1 2017 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro